Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29360544
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Circulating tumor cell-derived organoids: Current challenges and promises in
medical research and precision medicine
#MMPMID29360544
Praharaj PP
; Bhutia SK
; Nagrath S
; Bitting RL
; Deep G
Biochim Biophys Acta Rev Cancer
2018[Apr]; 1869
(2
): 117-127
PMID29360544
show ga
Traditional 2D cell cultures do not accurately recapitulate tumor heterogeneity,
and insufficient human cell lines are available. Patient-derived xenograft (PDX)
models more closely mimic clinical tumor heterogeneity, but are not useful for
high-throughput drug screening. Recently, patient-derived organoid cultures have
emerged as a novel technique to fill this critical need. Organoids maintain tumor
tissue heterogeneity and drug-resistance responses, and thus are useful for
high-throughput drug screening. Among various biological tissues used to produce
organoid cultures, circulating tumor cells (CTCs) are promising, due to relative
ease of ascertainment. CTC-derived organoids could help to acquire relevant
genetic and epigenetic information about tumors in real time, and screen and test
promising drugs. This could reduce the need for tissue biopsies, which are
painful and may be difficult depending on the tumor location. In this review, we
have focused on advances in CTC isolation and organoid culture methods, and their
potential applications in disease modeling and precision medicine.
free
free
free
